Clinical Outcomes of Patients with Advanced Solid Tumors of Cutaneous Capillary Hyperplasia Following Treatment with Camrelizumab: A Retrospective Case-Control Study

Abstract

Objective: To investigate the difference of clinical outcomes between patients with and without Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) after camrelizumab treatment. Methods: A retrospective, matched case-control study was designed. A total of 92 patients with advanced solid tumors treated with camrelizumab at xx hospital between July 2019 and October 2020 were included, of whom 16 patients developed RCCEP (RCCEP group) and the remaining 76 served as the control group. The primary endpoint is Progression-Free Survival (PFS), and the secondary endpoint is Objective Response Rate (ORR) and Overall Survival (OS). Multivariate Cox regression analysis is used to assess the relevant indicators of PFS. Results: Compared with the control group, significantly increased ORR was observed in patients with RCCEP (56.3% vs 19.7%) (P<0.05). The PFS was 13 months (5-15 months) in the RCCEP group and 6 months (2-11 months) in the control group. Compared with the control group, the PFS was significantly higher in the RCCEP group (HR=0.555, 95% CI: 0.278-0.985, P<0.05). In multivariate Cox regression, RCCEP remained statistically significant after excluding potential confounders (HR=0.312, 95% CI: 0.095-0.637, P<0.01) and was associated with PFS in patients. Conclusion: In camrelizumab treatment, the occurrence of RCCEP may be a marker of strong immune response and improved tumor treatment outcomes, and has potential predictive value in patient efficacy and prognosis.